A natural product secreted by a soil bacterium may lead to a new drug to treat tuberculosis, report scientists in a new study.
Pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, has been shown to be active against many of the drug-resistant types of the tuberculosis bacterium that no longer respond to treatment with the front-line drug isoniazid.
Tuberculosis causes up to two million deaths annually and there is a significant need for new drugs since the effectiveness of current antibiotics is compromised by the increasing prevalence of drug-resistant tuberculosis. The most effective drugs used to treat tuberculosis, like isoniazid and rifampicin, are not always effective.
The researchers identified a protein, the enzyme NADH-dependent enoyl(acyl carrier protein) reductase or InhA, the principal target for the antibiotic. "By selecting and isolating M. tuberculosis mutants resistant to pyridomycin and sequencing their genome we have found that a single gene named inhA is responsible for resistance to this natural product," said Stewart Cole, lead author of the study and a professor at the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.
The gene inhA is needed to produce the InhA protein, which is already known as a target for tuberculosis drug isoniazid. It turns out that pyridomycin can bind to the same pocket on the InhA enzyme as isoniazid but at a different site and in a way that involves a different sequence of molecular events. It is these differences that give pyridomycin the ability to overcome drug-resistant strains of mycobacteria.
"Nature and evolution have equipped some bacteria with potent defense mechanisms to protect them against other bugs that share their habitat. Screening natural products generated by these organisms is therefore a powerful way to find possible new drugs to fight infectious diseases," said Cole. "Using this approach we have shown that nature's antibiotic pyridomycin is a very selective killer of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis in humans. It is also active against mycobacteria that have developed resistance to front-line drug treatments such as isoniazid."
The scientists showed that in live bacteria treatment with pyridomycin leads to the depletion of mycolic acids, fatty acids that are an essential component of the bacterial cell wall.
"Our finding that pyridomycin kills Mycobacterium tuberculosis by inhibiting InhA, even in clinically isolated bacteria that are resistant to the drug isoniazid, provides a great opportunity to develop pyridomycin or a related agent for the treatment of drug-resistant tuberculosis," Cole said.
Published in EMBO Molecular Medicine.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Robot Tongue Identifies The Correct Beer Every Time
- Why Does The Public Worry About GM Foods But Embrace Biotech Medicine?
- Mystery Of Morgellons - Disease Or Delusion - Scientific Hypothesis Of Connection With Lyme Disease
- Did The Scottish Settle Iceland A Century Before The Norse?
- Highest Energy Collisions ? Not In My Book
- Editorial Independence Or Extortion? Frontiers Sacks 31 Editors
- Your Probiotic Probably Has Gluten
- "Hank,I am not sure if you were the reason for the PNAS thing. I remember learning about the..."
- "64. Combo of Overweight, High Sodium Intake Speeds Cell Aging in Teens. March 20th, 2014 http://blog..."
- " This pretty well destroys the Myth of second hand smoke: Lungs from pack-a-day smokers safe for..."
- "This is a good start, but describing the waste stream of nuclear power in terms of carbon production..."
- "Knowing this would a mitochondrial superoxide like MitoQ be beneficial or harmful?..."